Holen Sie sich die Stockscreener-App
10.04
1.83%
0.18
Handel nachbörslich:
10.15
0.11
+1.10%
Schlusskurs vom Vortag:
$9.86
Offen:
$9.91
24-Stunden-Volumen:
410.33K
Relative Volume:
0.80
Marktkapitalisierung:
$540.48M
Einnahmen:
$9.68M
Nettoeinkommen (Verlust:
$-244.09M
KGV:
-2.2141
EPS:
-4.5346
Netto-Cashflow:
$-168.85M
1W Leistung:
+8.54%
1M Leistung:
+4.69%
6M Leistung:
+1.83%
1J Leistung:
-7.55%
1-Tages-Spanne:
$9.88
$10.11
1-Wochen-Bereich:
$9.33
$10.12
52-Wochen-Spanne:
$4.32
$11.69
Prothena Corporation Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corporation Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
10.04 | 530.79M | 9.68M | -244.09M | -168.85M | -4.5346 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-04-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Oppenheimer | Outperform |
| 2021-05-26 | Eingeleitet | Citigroup | Buy |
| 2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
| 2018-04-05 | Bestätigt | Barclays | Overweight |
| 2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2017-09-29 | Bestätigt | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-12-21 | Eingeleitet | SunTrust | Buy |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-08-04 | Bestätigt | Barclays | Overweight |
| 2016-05-13 | Eingeleitet | Barclays | Overweight |
| 2016-02-19 | Bestätigt | Wedbush | Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Analyst Calls: How do insiders feel about Prothena Corporation plc2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Gap Down: Can Prothena Corporation plc be recession proofWeekly Trend Report & AI Driven Price Predictions - baoquankhu1.vn
Prothena Corp plc Stock: Clinical Milestones and Strategic Focus in Biotechnology Drive Investor Int - AD HOC NEWS
PRTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PRTA Technical Analysis & Stock Price Forecast - Intellectia AI
Understanding Momentum Shifts in (PRTA) - news.stocktradersdaily.com
Top Growth Companies With High Insider Ownership In March 2026 - simplywall.st
JPMorgan Chase & Co. Buys 608,814 Shares of Prothena Corporation plc $PRTA - MarketBeat
Aug Patterns: Will Prothena Corporation plc outperform its industry peersWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Stock Recap: Will Prothena Corporation plc benefit from rising consumer demandQuarterly Market Review & Weekly Hot Stock Watchlists - baoquankhu1.vn
Gainers Report: Will Prothena Corporation plc outperform tech stocks2026 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
Prothena (NASDAQ: PRTA) details 2026 AGM, pay and 2025 pipeline shifts - Stock Titan
When Can We Expect A Profit From Prothena Corporation plc (NASDAQ:PRTA)? - simplywall.st
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Prothena Q4 earnings meet estimates, pipeline progress in focus - MSN
Published on: 2026-03-27 01:04:54 - baoquankhu1.vn
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet - sharewise.com
Dow Update: Will Prothena Corporation plc benefit from rising consumer demandEntry Point & Low Risk High Reward Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Prothena stock rating on Parkinson’s data By Investing.com - Investing.com UK
Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Prothena Corp plc stock gains spotlight as partners Roche and Bristol-Myers Squibb showcase key clin - AD HOC NEWS
Prothena Partners Present Data Supporting Next Generation Treatme - The National Law Review
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 - Business Wire
Prothena Corp plc stock faces pressure amid biotech volatility and pipeline updates - AD HOC NEWS
Prothena authorizes up to $100 million share repurchase plan - MSN
Avoiding Lag: Real-Time Signals in (PRTA) Movement - Stock Traders Daily
History Review: Is Prothena Corporation plc attractive for institutional investors2026 Volume Leaders & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Biotech Headwinds Amid Pipeline Delays - AD HOC NEWS
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Headwinds Amid Biotech Volatility - AD HOC NEWS
Prothena Corporation plc $PRTA Stake Lessened by Prosight Management LP - MarketBeat
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Under Pressure Amid Biotech Volatility - AD HOC NEWS
Citizens reaffirms Prothena stock rating on Novo Nordisk milestone By Investing.com - Investing.com South Africa
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Pressure Amid Biotech Volatility - AD HOC NEWS
Prothena earns $50M milestone from Novo Nordisk for drug trial - Investing.com Nigeria
IPO Launch: Will Prothena Corporation plc outperform tech stocks2026 Movers & Weekly High Return Forecasts - baoquankhu1.vn
Prothena (NASDAQ:PRTA) Share Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Discipline and Rules-Based Execution in PRTA Response - Stock Traders Daily
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related t - PharmiWeb.com
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena Corporation Plc Receives $50 Million Clinical Milestone Payment From Novo Nordisk - marketscreener.com
PRTA Earnings History & Surprises | EPS & Revenue Results | PROTHENA CORP PLC (NASDAQ:PRTA) - ChartMill
Is Prothena Corporation plc stock a dividend growth opportunity2025 Buyback Activity & Real-Time Buy Zone Alerts - Naître et grandir
Aug Reactions: Is Prothena Corporation plc attractive for institutional investors - baoquankhu1.vn
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution (NASDAQ:PRTA) - Seeking Alpha
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade - Finviz
Prothena (NASDAQ:PRTA) Shares Up 8.7%Still a Buy? - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of “Hold” by Analysts - Defense World
Prothena Announces up to $100 Million Share Repurchase Plan - BioSpace
Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prothena Corporation Plc-Aktie (PRTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
| EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):